Drugs Monitor, Page 29

(28 July 2020) Tocilizumab- not associated with changes in 30-day mortality in patients with COVID-19 severe respiratory impairment

July 30, 2020

Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. https://doi.org/10.1016/j.jaut.2020.102511 In this multicenter retrospective cohort study we included adult patients with COVID-19, need of respiratory support, and elevated… Continue reading "(28 July 2020) Tocilizumab- not associated with changes in 30-day mortality in patients with COVID-19 severe respiratory impairment"

(28 July 2020) Remdesivir- associated with significantly greater recovery and 62% reduced odds of death

July 28, 2020

Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care https://doi.org/10.1093/cid/ciaa1041 NCT04292899/GS-US-540-5773 is an ongoing phase 3, randomized, open-label trial comparing two courses of remdesivir (remdesivir-cohort). Inclusion criteria were similar between studies: patients had confirmed SARS-CoV-2 infection, were hospitalized,… Continue reading "(28 July 2020) Remdesivir- associated with significantly greater recovery and 62% reduced odds of death"

(26 July 2020) Hydroxychloroquine- Postexposure therapy with HCQ did not prevent SARS-CoV-2 disease

July 27, 2020

A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease https://www.medrxiv.org/content/10.1101/2020.07.20.20157651v1 An open-label, cluster-randomized trial (NCT04304053) including asymptomatic contacts exposed to a PCR-positive Covid-19 case in Catalonia, Spain. Clusters were randomized to receive no specific therapy (control arm)… Continue reading "(26 July 2020) Hydroxychloroquine- Postexposure therapy with HCQ did not prevent SARS-CoV-2 disease"

(26 July 2020) Tocilizumab- Low-dose TCZ associated with rapid improvement

July 27, 2020

COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19 https://doi.org/10.1101/2020.07.20.20157503 Results from phase 2 trial (NCT04331795) of low-dose tocilizumab in hospitalized adult patients with Covid-19 are presented. A range of doses from 40 to 200 mg (low-dose tocilizumab) was evaluated, with… Continue reading "(26 July 2020) Tocilizumab- Low-dose TCZ associated with rapid improvement"

(23 July 2020) Hydroxychloroquine- alone or with azithromycin, did not improve clinical status at 15 days

July 25, 2020

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 https://www.nejm.org/doi/full/10.1056/NEJMoa2019014 A multicenter, randomized, open-label, three-group, controlled trial (NCT04322123. opens in new tab) involving hospitalized patients with suspected or confirmed Covid-19 who were receiving either no supplemental oxygen or a maximum of… Continue reading "(23 July 2020) Hydroxychloroquine- alone or with azithromycin, did not improve clinical status at 15 days"

(24 July 2020) Tocilizumab- associated with low mortality, and no major safety concerns in severe COVID-19 pneumonia

July 25, 2020

Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study https://doi.org/10.1016/j.jaut.2020.102523 The objective of this work was to describe the clinical characteristics and predictors of major outcomes in patients treated with tocilizumab (TCZ) for… Continue reading "(24 July 2020) Tocilizumab- associated with low mortality, and no major safety concerns in severe COVID-19 pneumonia"

(24 July 2020)- Hydroxychloroquine- data from prevention and early treatment trials did not suggest significant safety concerns

July 25, 2020

Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19 https://doi.org/10.1101/2020.07.16.20155531.this Results from three randomized, double-blind, placebo-controlled trials (NCT04308668, NCT04308668) investigating hydroxychloroquine as pre-exposure prophylaxis, post-exposure prophylaxis and early treatment for COVID-19 are presented. 2,795 participants were enrolled. Overall 2,324… Continue reading "(24 July 2020)- Hydroxychloroquine- data from prevention and early treatment trials did not suggest significant safety concerns"

(23 July 2020) Tocilizumab- Clinical status improved within 24 hours in 39%patients

July 25, 2020

Tocilizumab for patients with severe COVID-19: a retrospective, multi-centre study https://doi.org/10.1080/14787210.2020.1800453 This retrospective study included patients with severe COVID-19 requiring oxygen therapy who received tocilizumab in seven centers across Poland. We assessed on-treatment changes in clinical status and inflammatory markers. … Continue reading "(23 July 2020) Tocilizumab- Clinical status improved within 24 hours in 39%patients"

(22 July 2020) ACEIs/ARBs- No obvious influence on increasing the clinical severe situations of COVID‐19 patients with hypertension.

July 23, 2020

Efficacy of ACEIs/ARBs versus CCBs on the progression of COVID‐19 patients with hypertension in Wuhan: A hospital‐based retrospective cohort study https://doi.org/10.1002/jmv.26315 This retrospective single-center case series analyzed COVID-19 patients with hypertension, treated with ACEIs/ACEIs or CCBs . After PSM analysis,… Continue reading "(22 July 2020) ACEIs/ARBs- No obvious influence on increasing the clinical severe situations of COVID‐19 patients with hypertension."

(22 July 2020) Hydroxychloroquine- No clinical improvement observed

July 23, 2020

Clinical outcomes and adverse events in patients hospitalised with COVID ‐19, treated with off‐ label hydroxychloroquine and azithromycin https://doi.org/10.1111/bcp.14482 In a retrospective analysis of hospitalised patients that had a positive polymerase chain reaction (PCR) test for SARS-CoV-2 and received hydroxychloroquine… Continue reading "(22 July 2020) Hydroxychloroquine- No clinical improvement observed"